A 68930

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 571168

CAS#: 130465-45-1

Description: A 68930 is a dopamine D-1 receptor antagonist. It inhibits NLRP3 inflammasome activity. It may be used as a anti-stress and anti-ulcer agent in terms of its ability to modulate dopaminergic transmissions, especially in the gastrointestinal pathways.


Price and Availability

Size
Price

Size
Price

Size
Price

A 68930 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 571168
Name: A 68930
CAS#: 130465-45-1
Chemical Formula: C16H17NO3
Exact Mass: 271.1208
Molecular Weight: 271.32
Elemental Analysis: C, 70.83; H, 6.32; N, 5.16; O, 17.69


Synonym: A 68930; A-68930; A68930; A 70108; A-70108; A70108

IUPAC/Chemical Name: 1H-2-Benzopyran-5,6-diol, 1-(aminomethyl)-3,4-dihydro-3-phenyl-, (1R-cis)

InChi Key: SUHGRZPINGKYNV-GJZGRUSLSA-N

InChi Code: InChI=1S/C16H17NO3/c17-9-15-11-6-7-13(18)16(19)12(11)8-14(20-15)10-4-2-1-3-5-10/h1-7,14-15,18-19H,8-9,17H2/t14-,15-/m0/s1

SMILES Code: OC1=C2C[C@@H](C3=CC=CC=C3)O[C@@H](CN)C2=CC=C1O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Jiang W, Huang Y, He F, Liu J, Li M, Sun T, Ren W, Hou J, Zhu L. Dopamine D1 Receptor Agonist A-68930 Inhibits NLRP3 Inflammasome Activation, Controls Inflammation, and Alleviates Histopathology in a Rat Model of Spinal Cord Injury. Spine (Phila Pa 1976). 2016 Mar;41(6):E330-4. doi: 10.1097/BRS.0000000000001287. PubMed PMID: 26966979.

2: Jiang W, Li M, He F, Bian Z, Liu J, He Q, Wang X, Sun T, Zhu L. Dopamine D1 receptor agonist A-68930 inhibits NLRP3 inflammasome activation and protects rats from spinal cord injury-induced acute lung injury. Spinal Cord. 2016 Nov;54(11):951-956. doi: 10.1038/sc.2016.52. Epub 2016 Apr 12. PubMed PMID: 27067657.

3: Martin YC. The Discovery of Novel Selective D1 Dopaminergic Agonists: A-68930, A-77636, A-86929, and ABT-413. Int J Med Chem. 2011;2011:424535. doi: 10.1155/2011/424535. Epub 2011 Mar 24. Review. PubMed PMID: 25954518; PubMed Central PMCID: PMC4412209.

4: Rasheed N, Ahmad A, Singh N, Singh P, Mishra V, Banu N, Lohani M, Sharma S, Palit G. Differential response of A 68930 and sulpiride in stress-induced gastric ulcers in rats. Eur J Pharmacol. 2010 Sep 15;643(1):121-8. doi: 10.1016/j.ejphar.2010.06.032. Epub 2010 Jun 28. PubMed PMID: 20599913.

5: AI-Naser HA, Cooper SJ. A-68930, a novel, potent dopamine D1 receptor agonist: a microstructural analysis of its effects on feeding and other behaviour in the rat. Behav Pharmacol. 1994 Apr;5(2):210-218. PubMed PMID: 11224270.

6: Nergårdh R, Oerther S, Fredholm BB. Differences between A 68930 and SKF 82958 could suggest synergistic roles of D1 and D5 receptors. Pharmacol Biochem Behav. 2005 Nov;82(3):495-505. Epub 2005 Nov 28. PubMed PMID: 16318870.

7: Isacson R, Kull B, Wahlestedt C, Salmi P. A 68930 and dihydrexidine inhibit locomotor activity and d-amphetamine-induced hyperactivity in rats: a role of inhibitory dopamine D(1/5) receptors in the prefrontal cortex? Neuroscience. 2004;124(1):33-42. PubMed PMID: 14960337.

8: Salmi P, Ahlenius S. Sedative effects of the dopamine D1 receptor agonist A 68930 on rat open-field behavior. Neuroreport. 2000 Apr 27;11(6):1269-72. PubMed PMID: 10817605.

9: Daly SA, Waddington JL. The effects of clozapine on behavioural responses to the selective 'D1-like' dopamine receptor agonist, A 68930, and to the selective 'D2-like' agonist, RU 24213. Br J Pharmacol. 1994 Nov;113(3):839-44. PubMed PMID: 7858875; PubMed Central PMCID: PMC1510419.

10: Daly SA, Waddington JL. Behavioural evidence for "D-1-like" dopamine receptor subtypes in rat brain using the new isochroman agonist A 68930 and isoquinoline antagonist BW 737C. Psychopharmacology (Berl). 1993;113(1):45-50. PubMed PMID: 7862827.

11: Johnson KB, Criswell HE, Jensen KF, Simson PE, Mueller RA, Breese GR. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity. J Pharmacol Exp Ther. 1992 Aug;262(2):855-65. PubMed PMID: 1354257.

12: Christie MI, Smith GW. Cardiovascular and renal hemodynamic effects of A-68930 in the conscious dog: a comparison with fenoldopam. J Pharmacol Exp Ther. 1994 Feb;268(2):565-70. PubMed PMID: 7906731.

13: Kurokawa K, Mizuno K, Ohkuma S. Increase of ryanodine receptors by dopamine D1 receptors is negatively regulated by γ-aminobutyric acid type B receptors in primary cultures of mouse cerebral cortical neurons. J Neurosci Res. 2012 Aug;90(8):1626-38. doi: 10.1002/jnr.23058. Epub 2012 Apr 14. PubMed PMID: 22504960.

14: Deveney AM, Waddington JL. Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective "D1-like" dopamine receptor agonist A 68930 and selective "D2-like" agonist RU 24213. Psychopharmacology (Berl). 1996 Mar;124(1-2):40-9. PubMed PMID: 8935799.

15: Gronier B, Waters S, Ponten H. The dopaminergic stabilizer pridopidine increases neuronal activity of pyramidal neurons in the prefrontal cortex. J Neural Transm (Vienna). 2013 Sep;120(9):1281-94. doi: 10.1007/s00702-013-1002-4. Epub 2013 Mar 7. PubMed PMID: 23468085.

16: Rasheed N, Ahmad A, Pandey CP, Chaturvedi RK, Lohani M, Palit G. Differential response of central dopaminergic system in acute and chronic unpredictable stress models in rats. Neurochem Res. 2010 Jan;35(1):22-32. doi: 10.1007/s11064-009-0026-5. Epub 2009 Jul 1. PubMed PMID: 19568932.

17: Wigestrand MB, Fonnum F, Ivar Walaas S. Subunit-specific modulation of [(3)H]MK-801 binding to NMDA receptors mediated by dopamine receptor ligands in rodent brain. Neurochem Int. 2012 Jul;61(2):266-76. doi: 10.1016/j.neuint.2012.04.017. Epub 2012 Apr 25. PubMed PMID: 22561101.

18: Mystek P, Tworzydło M, Dziedzicka-Wasylewska M, Polit A. New insights into the model of dopamine D1 receptor and G-proteins interactions. Biochim Biophys Acta. 2015 Mar;1853(3):594-603. doi: 10.1016/j.bbamcr.2014.12.015. Epub 2014 Dec 17. PubMed PMID: 25527226.

19: Lange N, Hamann M, Shashidharan P, Richter A. Behavioural and pharmacological examinations in a transgenic mouse model of early-onset torsion dystonia. Pharmacol Biochem Behav. 2011 Feb;97(4):647-55. doi: 10.1016/j.pbb.2010.11.005. Epub 2010 Nov 13. PubMed PMID: 21078339.

20: Vermeulen RJ, Jongenelen CA, Langeveld CH, Wolters EC, Stoof JC, Drukarch B. Dopamine D1 receptor agonists display a different intrinsic activity in rat, monkey and human astrocytes. Eur J Pharmacol. 1994 Sep 15;269(1):121-5. PubMed PMID: 7828654.